id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-286525-0354438s	Lee, Todd C.	Tocilizumab versus the covid19 tempest: all’s well that ends well or much ado about nothing?	2020-09-29		.txt	text/plain	1440	85	46	One of the unexpected findings from this study was an observed lack of benefit from steroids in contrast to the RECOVERY randomized controlled trial results [4] or a recent meta-analysis of steroid trials in critically ill patients. The phase III COVACTA trial (NCT04317092) found tocilizumab did not reduce mortality in hospitalized patients with severe COVID-19 pneumonia [11] . Similarly a large trial of sarilumab (NCT04315298) in severe and critical COVID-19 was stopped by the data safety monitoring board due to lack of benefit and a potential signal for harm in non-ventilated patients [12] and a second international trial (NCT04327388) also failed to meet its primary or key secondary outcomes [13] . Reconciling their results with those from randomized control trials raises important questions about the causal effect of the hyperinflammatory response and its role in the development of severe COVID-19. Sanofi provides update on Kevzara® (sarilumab) Phase 3 trial in severe and critically ill COVID-19 patients outside the	./cache/cord-286525-0354438s.txt	./txt/cord-286525-0354438s.txt